Published November 6th, 2023
———————
Citron Research Reports on Apellis Pharmaceuticals (APLS)
Happy Days Are OVER for Apellis, as the Experts Give a Thumbs Down to Syfovre. Citron Expects FDA Warning Letter.
Citron Research was committed to ensuring that its return to short selling was marked by a report that would not only hinge on valuation concerns but also spotlight a company whose activities could be detrimental to the public interest. We held ourselves to the highest standard, making sure the information we disclosed would be irrefutable, lucid, and would empower the appropriate regulators to take necessary actions. With that we present Apellis Pharmaceuticals
